Research programme: erectile dysfunction gene therapy - University of Pittsburgh

Drug Profile

Research programme: erectile dysfunction gene therapy - University of Pittsburgh

Alternative Names: Post-radical prostatectomy erectile dysfunction gene therapy

Latest Information Update: 01 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Pittsburgh Medical Center
  • Class Gene therapies
  • Mechanism of Action Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Erectile dysfunction

Most Recent Events

  • 01 May 2007 This programme is still in active development
  • 05 May 2003 Preclinical trials in Erectile dysfunction in USA (Injection)
  • 05 May 2003 A preclinical study has been added to the Men's health pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top